{
    "name": "dextromethorphan/bupropion",
    "comment": "Rx",
    "other_names": [
        "Auvelity"
    ],
    "classes": [
        "Dopamine/Norepinephrine Reuptake Inhibitors",
        "NMDA Antagonists"
    ],
    "source": "https://reference.medscape.com/drug/auvelity-dextromethorphan-bupropion-4000211",
    "pregnancy": {
        "common": [
            "Not recommended during pregnancy",
            "Based on animal studies, may cause fetal harm when administered during pregnancy",
            "Encourage patients to register for the National Pregnancy Registry for Antidepressants at 1-866-961-2388 or online at ",
            "Owing to potential for neurotoxicity, advise patients that breastfeeding is not recommended during treatment and for 5 days after final dose"
        ],
        "specific": [
            {
                "type": "Clinical considerations ",
                "description": [
                    "A prospective, longitudinal study followed 201 pregnant women with history of major depressive disorder who were euthymic and taking antidepressants during pregnancy at the beginning of pregnancy",
                    "Women who discontinued antidepressants during pregnancy were more likely to experience relapse of major depression than women who continued antidepressants",
                    "Consider maternal risks of untreated depression and potential effects on fetus when discontinuing or changing treatment with antidepressant medications during pregnancy and postpartum"
                ]
            },
            {
                "type": "Dextromethorphan ",
                "description": [
                    "Neurotoxicity observed in juvenile rats treated with dextromethorphan/quinidine on postnatal day 7, which corresponds to third trimester of gestation through the first few months of life and may extend through the first 3 years of human life",
                    "Unknown if dextromethorphan is present in human milk; data are not available regarding effects on breastfed infant or on milk production"
                ]
            },
            {
                "type": "Bupropion ",
                "description": [
                    "There are no data on the effects of bupropion or its metabolites on milk production",
                    "Data from postmarketing reports are limited; use in lactating patients has not identified a clear association of adverse reactions in the breastfed infant"
                ]
            }
        ]
    },
    "lactation": {
        "common": []
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Antidepressants increased risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies ",
                "Closely monitor all antidepressant-treated patients for clinical worsening, and emergence of suicidal thoughts and behaviors ",
                "Not approved for use in pediatric patients"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "eliglustat",
            "description": {
                "common": "bupropion increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive  and intermediate metabolizers;  eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "isocarboxazid",
            "description": {
                "common": "isocarboxazid and bupropion both increase  dopaminergic effects. Contraindicated. Bupropion inhibits reuptake of dopamine and norepinephrine (NE), and MAOIs decrease metabolism of dopamine and NE; coadministration increases risk for hypertensive reactions; allow at least 14 days between discontinuation of MAOI and initiating bupropion"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "phenelzine",
            "description": {
                "common": "phenelzine and dextromethorphan both increase  serotonin levels. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "pimozide",
            "description": {
                "common": "bupropion will increase the level or effect of pimozide by  affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. Both bupropion and hydroxybupropion (major metabolite) are considered strong CYP2D6 inhibitors; additionally, bupropion and pimozide lower seizure threshold"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "procarbazine",
            "description": {
                "common": "procarbazine and dextromethorphan both increase  serotonin levels. Contraindicated. Combination is contraindicated within 2 weeks of MAOI use."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rasagiline",
            "description": {
                "common": "rasagiline and bupropion both increase  dopaminergic effects. Contraindicated. Bupropion inhibits reuptake of dopamine and norepinephrine (NE), and MAOIs decrease metabolism of dopamine and NE; coadministration increases risk for hypertensive reactions; allow at least 14 days between discontinuation of MAOI and initiating bupropion"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "safinamide",
            "description": {
                "common": "dextromethorphan, safinamide. Other (see comment). Contraindicated. \nComment: Coadministration of MAOIs and dextromethorphan has been reported to cause episodes of psychosis or bizarre behavior."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "selegiline",
            "description": {
                "common": "selegiline and bupropion both increase  dopaminergic effects. Contraindicated. Bupropion inhibits reuptake of dopamine and norepinephrine (NE), and MAOIs decrease metabolism of dopamine and NE; coadministration increases risk for hypertensive reactions; allow at least 14 days between discontinuation of MAOI and initiating bupropion"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "selegiline",
            "description": {
                "common": "selegiline and dextromethorphan both increase  serotonin levels. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "selegiline transdermal",
            "description": {
                "common": "selegiline transdermal and bupropion both increase  dopaminergic effects. Contraindicated. Bupropion inhibits reuptake of dopamine and norepinephrine (NE), and MAOIs decrease metabolism of dopamine and NE; coadministration increases risk for hypertensive reactions; allow at least 14 days between discontinuation of MAOI and initiating bupropion"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "tranylcypromine and bupropion both increase  dopaminergic effects. Contraindicated. Bupropion inhibits reuptake of dopamine and norepinephrine (NE), and MAOIs decrease metabolism of dopamine and NE; coadministration increases risk for hypertensive reactions; allow at least 14 days between discontinuation of MAOI and initiating bupropion"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir will increase the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP2B6 substrates. If not feasible, avoid use of abametapir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "amitriptyline and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amoxapine",
            "description": {
                "common": "amoxapine and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buspirone",
            "description": {
                "common": "buspirone and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "caffeine",
            "description": {
                "common": "caffeine increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "chlorpromazine increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "citalopram",
            "description": {
                "common": "citalopram and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clomipramine",
            "description": {
                "common": "clomipramine and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clozapine",
            "description": {
                "common": "clozapine increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "desipramine",
            "description": {
                "common": "desipramine and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclobenzaprine",
            "description": {
                "common": "bupropion and cyclobenzaprine both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "desvenlafaxine",
            "description": {
                "common": "dextromethorphan and desvenlafaxine both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "doxepin",
            "description": {
                "common": "doxepin and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "duloxetine",
            "description": {
                "common": "duloxetine increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "escitalopram",
            "description": {
                "common": "escitalopram increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole will decrease the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Avoid or Use Alternate Drug. Coadministration may decrease plasma concentrations of CYP2B6 substrates owing to fexinidazole inducing CYP2B6."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "fluoxetine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "fluoxetine increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine increases toxicity of bupropion by Other (see comment). Avoid or Use Alternate Drug. \nComment: May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "grapefruit",
            "description": {
                "common": "grapefruit will increase the level or effect of dextromethorphan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "iobenguane I 131",
            "description": {
                "common": "bupropion will decrease the level or effect of iobenguane I 131 by  Other (see comment). Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Do not administer these drugs until at least 7 days after each iobenguane dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "imipramine",
            "description": {
                "common": "imipramine and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levomilnacipran",
            "description": {
                "common": "levomilnacipran and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "linezolid",
            "description": {
                "common": "bupropion, linezolid. serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lofepramine",
            "description": {
                "common": "lofepramine and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lorcaserin",
            "description": {
                "common": "bupropion and lorcaserin both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lorcaserin",
            "description": {
                "common": "dextromethorphan and lorcaserin both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "maprotiline",
            "description": {
                "common": "maprotiline and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "memantine",
            "description": {
                "common": "memantine, dextromethorphan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "meperidine",
            "description": {
                "common": "dextromethorphan and meperidine both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methylene blue",
            "description": {
                "common": "methylene blue and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoclopramide intranasal",
            "description": {
                "common": "bupropion will increase the level or effect of metoclopramide intranasal by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Concurrent use of metoclopramide intranasal and strong CYP2D6 inhibitors is not recommended since the metoclopramide intranasal dose cannot be adjusted."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "milnacipran",
            "description": {
                "common": "milnacipran and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "milnacipran",
            "description": {
                "common": "milnacipran increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "nortriptyline and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olopatadine intranasal",
            "description": {
                "common": "bupropion and olopatadine intranasal both increase  sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ozanimod",
            "description": {
                "common": "ozanimod increases toxicity of bupropion by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "paroxetine",
            "description": {
                "common": "paroxetine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "protriptyline",
            "description": {
                "common": "protriptyline and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tedizolid",
            "description": {
                "common": "tedizolid, bupropion.\nEither increases levels of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. both increase serotonin levels; increased risk of serotonin syndrome."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "selegiline transdermal",
            "description": {
                "common": "selegiline transdermal and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "dextromethorphan and St John's Wort both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "theophylline",
            "description": {
                "common": "theophylline increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thioridazine",
            "description": {
                "common": "bupropion will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trazodone",
            "description": {
                "common": "trazodone increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trimipramine",
            "description": {
                "common": "trimipramine and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "venlafaxine",
            "description": {
                "common": "venlafaxine increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "venlafaxine",
            "description": {
                "common": "venlafaxine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vilazodone",
            "description": {
                "common": "dextromethorphan, vilazodone.\nEither increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug. Concomitant therapy should be discontinued immediately if signs or symptoms of serotonin syndrome emerge and supportive symptomatic treatment should be initiated.  ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vortioxetine",
            "description": {
                "common": "bupropion, vortioxetine.\nEither increases effects of the other by serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "5-HTP",
            "description": {
                "common": "5-HTP and dextromethorphan both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abiraterone",
            "description": {
                "common": "abiraterone increases levels of dextromethorphan by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "almotriptan",
            "description": {
                "common": "almotriptan and dextromethorphan both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amantadine",
            "description": {
                "common": "amantadine, bupropion. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential CNS toxicity d/t synergistic central dopamine effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amifampridine",
            "description": {
                "common": "bupropion increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "amitriptyline increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital, bupropion. increasing metabolism. Use Caution/Monitor. Decr levels of bupropion, but incr levels of active metabolites. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxapine",
            "description": {
                "common": "amoxapine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amphetamine",
            "description": {
                "common": "amphetamine, dextromethorphan.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when amphemtamines are coadministered with dextromethorphan. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "dextromethorphan, aripiprazole. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "artemether/lumefantrine",
            "description": {
                "common": "artemether/lumefantrine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atomoxetine",
            "description": {
                "common": "bupropion will increase the level or effect of atomoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "dextromethorphan, asenapine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "bupropion will increase the level or effect of benzhydrocodone/acetaminophen by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone [benzhydrocodone is prodrug of hydrocodone]) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betaxolol",
            "description": {
                "common": "bupropion will increase the level or effect of betaxolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "bupropion will increase the level or effect of brexpiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Administer half of the usual brexpiprazole dose when coadministered with strong CYP2D6 inhibitors. If also administered with a strong/moderate CYP3A4 inhibitor, administer a quarter of brexpiprazole dose. NOTE: In MDD clinical trials, brexpiprazole dosage was not adjusted for strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine); thus, CYP considerations are already factored into general dosing recommendations and brexpiprazole may be administered without dosage adjustment in patients with MDD."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupropion",
            "description": {
                "common": "bupropion will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital, bupropion. increasing metabolism. Use Caution/Monitor. Decr levels of bupropion, but incr levels of active metabolites. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital, bupropion. increasing metabolism. Use Caution/Monitor. Decr levels of bupropion, but incr levels of active metabolites. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cannabidiol",
            "description": {
                "common": "cannabidiol, bupropion. affecting hepatic enzyme CYP2B6 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP2B6 induction and inhibition with the coadministration of CYP2B6 substrates and cannabidiol, consider reducing dosage adjustment of CYP2B6 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cariprazine",
            "description": {
                "common": "dextromethorphan, cariprazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carvedilol",
            "description": {
                "common": "bupropion will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate will decrease the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP2B6 substrate, as needed, when coadministered with cenobamate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloroquine",
            "description": {
                "common": "bupropion will increase the level or effect of chloroquine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "bupropion will increase the level or effect of chlorpromazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cinacalcet",
            "description": {
                "common": "bupropion will increase the level or effect of cinacalcet by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "bupropion will increase the level or effect of citalopram by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clobazam",
            "description": {
                "common": "clobazam will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "clomipramine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clopidogrel",
            "description": {
                "common": "clopidogrel will increase the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Plasma concentrations of bupropion may be significantly increased when coadministered with clopidogrel or other CYP2B6 inhibitors. The increase in plasma bupropion concentrations may cause an increase in adverse reactions including tremor, headache, insomnia, dry mouth, nausea, or seizures."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clozapine",
            "description": {
                "common": "dextromethorphan, clozapine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cocaine topical",
            "description": {
                "common": "cocaine topical and dextromethorphan both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "codeine",
            "description": {
                "common": "bupropion will decrease the level or effect of codeine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Prevents the conversion of codeine to its active metabolite morphine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "daridorexant",
            "description": {
                "common": "bupropion and daridorexant both increase  sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desipramine",
            "description": {
                "common": "bupropion will increase the level or effect of desipramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desvenlafaxine",
            "description": {
                "common": "desvenlafaxine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deutetrabenazine",
            "description": {
                "common": "bupropion will increase the level or effect of deutetrabenazine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Strong CYP2D6 inhibitors increase the systemic exposure to the active dihydro-metabolites of deutetrabenazine by approximately 3-fold. Do not exceed 18 mg/dose and 36 mg/day of deutetrabenazine if coadministered with strong CYP2D6 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexfenfluramine",
            "description": {
                "common": "dexfenfluramine and dextromethorphan both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextroamphetamine",
            "description": {
                "common": "dextroamphetamine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextroamphetamine transdermal",
            "description": {
                "common": "dextroamphetamine transdermal, dextromethorphan.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when amphemtamines are coadministered with dextromethorphan. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextromethorphan",
            "description": {
                "common": "bupropion will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dihydroergotamine",
            "description": {
                "common": "dextromethorphan and dihydroergotamine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam intranasal",
            "description": {
                "common": "diazepam intranasal, bupropion.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "difelikefalin",
            "description": {
                "common": "difelikefalin and bupropion both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "bupropion will decrease the level or effect of digoxin by  Other (see comment). Use Caution/Monitor. Monitor for decreased digoxin concentrations; bupropion may induce OATP4C1 transporter, which is involved in digoxin renal elimination"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dihydroergotamine intranasal",
            "description": {
                "common": "dextromethorphan and dihydroergotamine intranasal both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin",
            "description": {
                "common": "bupropion will increase the level or effect of doxepin by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duloxetine",
            "description": {
                "common": "bupropion will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will decrease the level or effect of bupropion by  increasing metabolism. Use Caution/Monitor. Coadministration with hepatic inducers reduced bupropion AUC and Cmax; hydroxybupropion (active metabolite) Cmax was increased "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eletriptan",
            "description": {
                "common": "eletriptan and dextromethorphan both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eluxadoline",
            "description": {
                "common": "bupropion increases levels of eluxadoline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. As a precautionary measure due to incomplete information on the metabolism of eluxadoline, use caution when coadministered with strong CYP2D6 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of bupropion by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ergotamine",
            "description": {
                "common": "dextromethorphan and ergotamine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenfluramine",
            "description": {
                "common": "fenfluramine, bupropion.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fesoterodine",
            "description": {
                "common": "bupropion will increase the level or effect of fesoterodine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "dextromethorphan, fluphenazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flecainide",
            "description": {
                "common": "bupropion will increase the level or effect of flecainide by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Coadministration of bupropion and flecainide should be approached with caution and should be initiated at the lower end of the dose range of flecainide. If bupropion is added to the treatment regimen of a patient already receiving flecainide, consider decreasing the dose of flecainide."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "bupropion will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "bupropion will increase the level or effect of fluphenazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine will increase the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "frovatriptan",
            "description": {
                "common": "frovatriptan and dextromethorphan both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gabapentin",
            "description": {
                "common": "gabapentin, bupropion.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gabapentin enacarbil",
            "description": {
                "common": "gabapentin enacarbil, bupropion.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "galantamine",
            "description": {
                "common": "bupropion will increase the level or effect of galantamine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ganaxolone",
            "description": {
                "common": "bupropion and ganaxolone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "bupropion will increase the level or effect of haloperidol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocodone",
            "description": {
                "common": "bupropion will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "dextromethorphan, iloperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydromorphone",
            "description": {
                "common": "bupropion will increase the level or effect of hydromorphone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "bupropion will increase the level or effect of iloperidone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "bupropion will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ioflupane I 123",
            "description": {
                "common": "bupropion decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoniazid",
            "description": {
                "common": "dextromethorphan and isoniazid both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "L-tryptophan",
            "description": {
                "common": "dextromethorphan and L-tryptophan both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lasmiditan",
            "description": {
                "common": "lasmiditan, bupropion.\nEither increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lemborexant",
            "description": {
                "common": "lemborexant will decrease the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Modify Therapy/Monitor Closely. Monitor CYP2B6 substrate for adequate clinical response. Consider increasing the CYP2B6 substrate dose according to specific prescribing recommendations."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letermovir",
            "description": {
                "common": "letermovir increases levels of dextromethorphan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levodopa",
            "description": {
                "common": "bupropion increases effects of levodopa by pharmacodynamic synergism. Use Caution/Monitor. There is a higher incidence of adverse reactions with concurrent use of bupropion with levodopa. Use small initial dosages and small, gradual dosage increases of bupropion."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisdexamfetamine",
            "description": {
                "common": "lisdexamfetamine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lithium",
            "description": {
                "common": "dextromethorphan and lithium both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofepramine",
            "description": {
                "common": "bupropion will increase the level or effect of lofepramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofexidine",
            "description": {
                "common": "bupropion will increase the level or effect of lofexidine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Concomitant use of lofexidine with strong CYP2D6 inhibitors may increase lofexidine plasma levels. Monitor for symptoms of orthostasis and bradycardia if coadministered with a CYP2D6 inhibitor. Consider lofexidine dose reduction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loratadine",
            "description": {
                "common": "bupropion will increase the level or effect of loratadine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine",
            "description": {
                "common": "dextromethorphan, loxapine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine inhaled",
            "description": {
                "common": "dextromethorphan, loxapine inhaled. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lsd",
            "description": {
                "common": "dextromethorphan and lsd both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lumacaftor/ivacaftor",
            "description": {
                "common": "lumacaftor/ivacaftor, bupropion. affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2B6 substrates. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lumefantrine",
            "description": {
                "common": "lumefantrine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "dextromethorphan, lurasidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maprotiline",
            "description": {
                "common": "maprotiline increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "dextromethorphan and mirtazapine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metformin",
            "description": {
                "common": "bupropion increases levels of metformin by Other (see comment). Use Caution/Monitor. \nComment: Bupropion may inhibit OCT2 mediated renal excretion of metformin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methamphetamine",
            "description": {
                "common": "bupropion will increase the level or effect of methamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylenedioxymethamphetamine",
            "description": {
                "common": "methylenedioxymethamphetamine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoprolol",
            "description": {
                "common": "bupropion will increase the level or effect of metoprolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mexiletine",
            "description": {
                "common": "bupropion will increase the level or effect of mexiletine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone will increase the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mipomersen",
            "description": {
                "common": "mipomersen, bupropion.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Both drugs have potential to increase hepatic enzymes; monitor LFTs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "bupropion will increase the level or effect of mirtazapine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "molindone",
            "description": {
                "common": "dextromethorphan, molindone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "morphine",
            "description": {
                "common": "dextromethorphan and morphine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naratriptan",
            "description": {
                "common": "naratriptan and dextromethorphan both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nebivolol",
            "description": {
                "common": "bupropion will increase the level or effect of nebivolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir, bupropion. decreasing metabolism. Use Caution/Monitor. Incr levels of bupropion, but decr levels of active metabolites. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nilotinib",
            "description": {
                "common": "nilotinib, bupropion. increasing metabolism. Use Caution/Monitor. Decr levels of bupropion, but incr levels of active metabolites. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nirmatrelvir",
            "description": {
                "common": "nirmatrelvir will decrease the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Buproion extensively metabolized by CYP2B6 to active metabolite. Monitor for adequate clinical response to bupropion when coadministered with CYP2B6 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nirmatrelvir/ritonavir",
            "description": {
                "common": "nirmatrelvir/ritonavir will decrease the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Bupropion is extensively metabolized by CYP2B6 to active metabolite. Monitor for adequate clinical response to bupropion when coadministered with CYP2B6 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "bupropion will increase the level or effect of nortriptyline by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olanzapine",
            "description": {
                "common": "dextromethorphan, olanzapine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oliceridine",
            "description": {
                "common": "bupropion will increase the level or effect of oliceridine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. If concomitant use is necessary, may require less frequent oliceridine dosing. Closely monitor for respiratory depression and sedation and titrate subsequent doses accordingly. If inhibitor is discontinued, consider increase oliceridine dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxycodone",
            "description": {
                "common": "bupropion will increase the level or effect of oxycodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paliperidone",
            "description": {
                "common": "dextromethorphan, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "panobinostat",
            "description": {
                "common": "panobinostat will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Panobinostat can increase the levels and effects of sensitive CYP2D6 substrates or those with a narrow therapeutic index CYP2D6."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pazopanib",
            "description": {
                "common": "pazopanib increases levels of dextromethorphan by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "peginterferon alfa 2b",
            "description": {
                "common": "peginterferon alfa 2b, dextromethorphan. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentazocine",
            "description": {
                "common": "dextromethorphan and pentazocine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital, bupropion. increasing metabolism. Use Caution/Monitor. Decr levels of bupropion, but incr levels of active metabolites. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perphenazine",
            "description": {
                "common": "dextromethorphan, perphenazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of bupropion by  increasing metabolism. Use Caution/Monitor. Decrease levels of bupropion."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimavanserin",
            "description": {
                "common": "dextromethorphan, pimavanserin. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimozide",
            "description": {
                "common": "dextromethorphan, pimozide. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pitolisant",
            "description": {
                "common": "bupropion will increase the level or effect of pitolisant by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. If coadministered with strong CYP2D6 inhibitors, initiate pitolisant at 8.9 mg/day and increase after 7 days to maximum of 17.8 mg/day. For patients currently taking pitolisant, reduce pitolisant dose by half upon initiating strong CYP2D6 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pivmecillinam",
            "description": {
                "common": "pivmecillinam increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pregabalin",
            "description": {
                "common": "pregabalin, bupropion.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone, bupropion. increasing metabolism. Use Caution/Monitor. Decr levels of bupropion, but incr levels of active metabolites. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prochlorperazine",
            "description": {
                "common": "bupropion will increase the level or effect of prochlorperazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "promethazine",
            "description": {
                "common": "bupropion will increase the level or effect of promethazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propafenone",
            "description": {
                "common": "bupropion will increase the level or effect of propafenone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "bupropion will increase the level or effect of propranolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protriptyline",
            "description": {
                "common": "protriptyline increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quetiapine",
            "description": {
                "common": "dextromethorphan, quetiapine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinidine",
            "description": {
                "common": "quinidine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "remimazolam",
            "description": {
                "common": "remimazolam, bupropion.\nEither increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risperidone",
            "description": {
                "common": "dextromethorphan, risperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir decreases levels of bupropion by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Ritonavir decreases levels of bupropion by inducing CYP2B6. Bupropion levels decreased by 20-80%, increased doses of bupropion may be required ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rizatriptan",
            "description": {
                "common": "rizatriptan and dextromethorphan both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rolapitant",
            "description": {
                "common": "rolapitant will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor for adverse reactions when unable to avoid coadministration with narrow therapeutic index CYP2D6 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "SAMe",
            "description": {
                "common": "dextromethorphan and SAMe both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital, bupropion. increasing metabolism. Use Caution/Monitor. Decr levels of bupropion, but incr levels of active metabolites. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline increases levels of bupropion by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Sertraline may inhibit hydroxylation of bupropion to its major active metabolite hydroxybupropion."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "solriamfetol",
            "description": {
                "common": "bupropion and solriamfetol both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sorafenib",
            "description": {
                "common": "sorafenib, bupropion. decreasing metabolism. Use Caution/Monitor. Incr levels of bupropion, but decr levels of active metabolites. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sparsentan",
            "description": {
                "common": "sparsentan will decrease the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Sparsentan (a CYP2B6 inducer) decreases exposure of CYP2B6 substrates and reduces efficacy related to these substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, bupropion. affecting hepatic enzyme CYP2B6 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP2B6 inhibitor and inducer. Monitor CYP2B6 substrates coadministered with stiripentol for increased or decreased effects. CYP2B6 substrates may require dosage adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sufentanil SL",
            "description": {
                "common": "sufentanil SL, bupropion.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sumatriptan",
            "description": {
                "common": "sumatriptan and dextromethorphan both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sumatriptan intranasal",
            "description": {
                "common": "sumatriptan intranasal and dextromethorphan both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tamoxifen",
            "description": {
                "common": "bupropion decreases effects of tamoxifen by decreasing metabolism. Use Caution/Monitor. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tamsulosin",
            "description": {
                "common": "bupropion increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tapentadol",
            "description": {
                "common": "bupropion and tapentadol both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "telotristat ethyl",
            "description": {
                "common": "telotristat ethyl will decrease the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Consider increasing dosage of interacting drug, if necessary"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "temocillin",
            "description": {
                "common": "temocillin increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thiothixene",
            "description": {
                "common": "dextromethorphan, thiothixene. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ticarcillin",
            "description": {
                "common": "ticarcillin increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "timolol",
            "description": {
                "common": "bupropion will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolterodine",
            "description": {
                "common": "bupropion will increase the level or effect of tolterodine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tramadol",
            "description": {
                "common": "bupropion will increase the level or effect of tramadol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "dextromethorphan, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimipramine",
            "description": {
                "common": "trimipramine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ziprasidone",
            "description": {
                "common": "dextromethorphan, ziprasidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valbenazine",
            "description": {
                "common": "bupropion will increase the level or effect of valbenazine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Consider reducing valbenazine dose based on tolerability if coadministered with a strong CYP2D6 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "venlafaxine",
            "description": {
                "common": "bupropion will increase the level or effect of venlafaxine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zolmitriptan",
            "description": {
                "common": "zolmitriptan and dextromethorphan both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "armodafinil",
            "description": {
                "common": "armodafinil, bupropion. increasing metabolism. Minor/Significance Unknown. Decr levels of bupropion, but incr levels of active metabolites. ."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine decreases levels of bupropion by increasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cefamandole",
            "description": {
                "common": "cefamandole increases toxicity of bupropion by unspecified interaction mechanism. Minor/Significance Unknown. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cefpirome",
            "description": {
                "common": "cefpirome increases toxicity of bupropion by unspecified interaction mechanism. Minor/Significance Unknown. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "celecoxib",
            "description": {
                "common": "celecoxib will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chloroquine",
            "description": {
                "common": "chloroquine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cimetidine",
            "description": {
                "common": "cimetidine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "darifenacin",
            "description": {
                "common": "darifenacin will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexfenfluramine",
            "description": {
                "common": "bupropion will increase the level or effect of dexfenfluramine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diphenhydramine",
            "description": {
                "common": "diphenhydramine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "donepezil",
            "description": {
                "common": "bupropion will increase the level or effect of donepezil by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dronedarone",
            "description": {
                "common": "dronedarone will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "encainide",
            "description": {
                "common": "bupropion will increase the level or effect of encainide by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethanol",
            "description": {
                "common": "ethanol, bupropion.\nEither increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "fluphenazine increases toxicity of bupropion by unspecified interaction mechanism. Minor/Significance Unknown. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "haloperidol",
            "description": {
                "common": "haloperidol will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "imatinib",
            "description": {
                "common": "imatinib will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "maraviroc",
            "description": {
                "common": "maraviroc will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "marijuana",
            "description": {
                "common": "marijuana will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "meperidine",
            "description": {
                "common": "meperidine increases toxicity of bupropion by unspecified interaction mechanism. Minor/Significance Unknown. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "modafinil",
            "description": {
                "common": "modafinil, bupropion. increasing metabolism. Minor/Significance Unknown. Decr levels of bupropion, but incr levels of active metabolites. ."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nicotine inhaled",
            "description": {
                "common": "bupropion, nicotine inhaled.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypertension."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nicotine intranasal",
            "description": {
                "common": "bupropion, nicotine intranasal.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypertension."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nilotinib",
            "description": {
                "common": "nilotinib will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "parecoxib",
            "description": {
                "common": "parecoxib will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "perhexiline",
            "description": {
                "common": "bupropion will increase the level or effect of perhexiline by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "perphenazine",
            "description": {
                "common": "perphenazine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "promazine",
            "description": {
                "common": "bupropion will increase the level or effect of promazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "promethazine",
            "description": {
                "common": "promethazine increases toxicity of bupropion by unspecified interaction mechanism. Minor/Significance Unknown. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "propafenone",
            "description": {
                "common": "propafenone will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "quinacrine",
            "description": {
                "common": "quinacrine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ranolazine",
            "description": {
                "common": "ranolazine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "thioridazine",
            "description": {
                "common": "thioridazine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "trifluoperazine increases toxicity of bupropion by unspecified interaction mechanism. Minor/Significance Unknown. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tropisetron",
            "description": {
                "common": "bupropion will increase the level or effect of tropisetron by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Drowsiness",
            "percent": null
        },
        {
            "name": "dizziness",
            "percent": null
        },
        {
            "name": "nervousness or restlessness",
            "percent": null
        },
        {
            "name": "nausea",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "and stomach pain",
            "percent": null
        },
        {
            "name": "Body",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "myalgia",
            "percent": null
        },
        {
            "name": "and fever with rash and other symptoms suggestive of delayed hypersensitivity",
            "percent": null
        },
        {
            "name": "Cardiovascular",
            "percent": null
        },
        {
            "name": "Complete atrioventricular block",
            "percent": null
        },
        {
            "name": "extrasystoles",
            "percent": null
        },
        {
            "name": "hypotension",
            "percent": null
        },
        {
            "name": "hypertension",
            "percent": null
        },
        {
            "name": "in some cases severe",
            "percent": null
        },
        {
            "name": "phlebitis",
            "percent": null
        },
        {
            "name": "and pulmonary embolism",
            "percent": null
        },
        {
            "name": "Digestive",
            "percent": null
        },
        {
            "name": "Colitis",
            "percent": null
        },
        {
            "name": "esophagitis",
            "percent": null
        },
        {
            "name": "gastrointestinal hemorrhage",
            "percent": null
        },
        {
            "name": "gum hemorrhage",
            "percent": null
        },
        {
            "name": "hepatitis",
            "percent": null
        },
        {
            "name": "intestinal perforation",
            "percent": null
        },
        {
            "name": "pancreatitis",
            "percent": null
        },
        {
            "name": "and stomach ulcer",
            "percent": null
        },
        {
            "name": "Endocrine",
            "percent": null
        },
        {
            "name": "Hyperglycemia",
            "percent": null
        },
        {
            "name": "hypoglycemia",
            "percent": null
        },
        {
            "name": "hyponatremia",
            "percent": null
        },
        {
            "name": "and syndrome of inappropriate antidiuretic hormone secretion",
            "percent": null
        },
        {
            "name": "Hemic and Lymphatic",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "leukocytosis",
            "percent": null
        },
        {
            "name": "leukopenia",
            "percent": null
        },
        {
            "name": "lymphadenopathy",
            "percent": null
        },
        {
            "name": "pancytopenia",
            "percent": null
        },
        {
            "name": "and thrombocytopenia",
            "percent": null
        },
        {
            "name": "Metabolic and nutritional",
            "percent": null
        },
        {
            "name": "Glycosuria",
            "percent": null
        },
        {
            "name": "Musculoskeletal",
            "percent": null
        },
        {
            "name": "Muscle rigidity",
            "percent": null
        },
        {
            "name": "fever",
            "percent": null
        },
        {
            "name": "rhabdomyolysis and muscle weakness",
            "percent": null
        },
        {
            "name": "Nervous system",
            "percent": null
        },
        {
            "name": "Abnormal electroencephalogram",
            "percent": null
        },
        {
            "name": "EEG",
            "percent": null
        },
        {
            "name": "aggression",
            "percent": null
        },
        {
            "name": "agitation",
            "percent": null
        },
        {
            "name": "akinesia",
            "percent": null
        },
        {
            "name": "aphasia",
            "percent": null
        },
        {
            "name": "coma",
            "percent": null
        },
        {
            "name": "completed suicide",
            "percent": null
        },
        {
            "name": "delirium",
            "percent": null
        },
        {
            "name": "delusions",
            "percent": null
        },
        {
            "name": "depression",
            "percent": null
        },
        {
            "name": "dysarthria",
            "percent": null
        },
        {
            "name": "euphoria",
            "percent": null
        },
        {
            "name": "extrapyramidal syndrome",
            "percent": null
        },
        {
            "name": "dyskinesia",
            "percent": null
        },
        {
            "name": "dystonia",
            "percent": null
        },
        {
            "name": "hypokinesia",
            "percent": null
        },
        {
            "name": "parkinsonism",
            "percent": null
        },
        {
            "name": "hallucinations",
            "percent": null
        },
        {
            "name": "homicidal ideation",
            "percent": null
        },
        {
            "name": "hostility",
            "percent": null
        },
        {
            "name": "increased libido",
            "percent": null
        },
        {
            "name": "manic reaction",
            "percent": null
        },
        {
            "name": "neuralgia",
            "percent": null
        },
        {
            "name": "neuropathy",
            "percent": null
        },
        {
            "name": "panic",
            "percent": null
        },
        {
            "name": "paranoid ideation",
            "percent": null
        },
        {
            "name": "psychosis",
            "percent": null
        },
        {
            "name": "restlessness",
            "percent": null
        },
        {
            "name": "suicide ideation",
            "percent": null
        },
        {
            "name": "suicide attempt",
            "percent": null
        },
        {
            "name": "and unmasking tardive dyskinesia",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "Pneumonia",
            "percent": null
        },
        {
            "name": "Skin",
            "percent": null
        },
        {
            "name": "Alopecia",
            "percent": null
        },
        {
            "name": "angioedema",
            "percent": null
        },
        {
            "name": "exfoliative dermatitis",
            "percent": null
        },
        {
            "name": "hirsutism",
            "percent": null
        },
        {
            "name": "and Stevens",
            "percent": null
        },
        {
            "name": "Johnson syndrome",
            "percent": null
        },
        {
            "name": "Special senses",
            "percent": null
        },
        {
            "name": "Deafness",
            "percent": null
        },
        {
            "name": "increased intraocular pressure",
            "percent": null
        },
        {
            "name": "and mydriasis",
            "percent": null
        }
    ]
}